NASDAQ:MCRB - Seres Therapeutics Stock Price, News & Analysis

$3.65
-0.12 (-3.18 %)
(As of 08/25/2019 04:00 PM ET)
Today's Range
$3.4650
Now: $3.65
$3.76
50-Day Range
$2.19
MA: $2.89
$3.76
52-Week Range
$2.02
Now: $3.65
$9.26
Volume328,058 shs
Average Volume294,452 shs
Market Capitalization$255.17 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MCRB
CUSIPN/A
Phone617-945-9626

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.27 million
Book Value($0.26) per share

Profitability

Net Income$-98,940,000.00
Net Margins-198.12%

Miscellaneous

Employees145
Market Cap$255.17 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.


Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics Inc (NASDAQ:MCRB) released its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.17. The biotechnology company had revenue of $12.53 million for the quarter, compared to analysts' expectations of $10.29 million. View Seres Therapeutics' Earnings History.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Seres Therapeutics.

What price target have analysts set for MCRB?

6 equities research analysts have issued 1 year price targets for Seres Therapeutics' shares. Their forecasts range from $4.00 to $16.00. On average, they expect Seres Therapeutics' share price to reach $11.60 in the next year. This suggests a possible upside of 217.8% from the stock's current price. View Analyst Price Targets for Seres Therapeutics.

What is the consensus analysts' recommendation for Seres Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seres Therapeutics.

What are Wall Street analysts saying about Seres Therapeutics stock?

Here are some recent quotes from research analysts about Seres Therapeutics stock:
  • 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (7/4/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 price target. We believe Seres is at the forefront of unlocking the potential for microbiome modulation to generate novel methods by which to treat medical conditions. Continuing with the company’s re-prioritization, Seres announced modifications to the ongoing SER-109 Phase 3 trial to potentially accelerate the top-line data readout. We believe recovery of the stock could be supported by this and the other recent changes that may expedite data demonstrating that microbiome-based therapies have their desired effects." (5/7/2019)
  • 3. HC Wainwright analysts commented, "We reiterate our Buy rating with an $8 PT, which was derived by discounting free cash flows for each year by 25%, dividing them by our projected number of shares for each year to account for the effects of share dilution, using a 2% terminal growth rate, and a 72% probability-of-success." (5/3/2019)

Has Seres Therapeutics been receiving favorable news coverage?

Media headlines about MCRB stock have been trending positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Seres Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Seres Therapeutics.

Are investors shorting Seres Therapeutics?

Seres Therapeutics saw a increase in short interest in July. As of July 15th, there was short interest totalling 4,747,400 shares, an increase of 9.7% from the June 15th total of 4,328,500 shares. Based on an average daily volume of 561,100 shares, the short-interest ratio is currently 8.5 days. Approximately 22.9% of the company's stock are sold short. View Seres Therapeutics' Current Options Chain.

Who are some of Seres Therapeutics' key competitors?

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), Juno Therapeutics (JUNO), TherapeuticsMD (TXMD), Walt Disney (DIS), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Anavex Life Sciences (AVXL), Novavax (NVAX), Progenics Pharmaceuticals (PGNX) and Sangamo Therapeutics (SGMO).

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the folowing people:
  • Mr. Eric D. Shaff, Pres, CEO & Director (Age 43)
  • Mr. Marcus Chapman, VP of Fin., Principal Financial & Accounting Officer (Age 48)
  • Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 58)
  • Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 44)
  • Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (17.13%), Nikko Asset Management Americas Inc. (11.79%), Sumitomo Mitsui Trust Holdings Inc. (11.78%), Perceptive Advisors LLC (3.58%), BlackRock Inc. (5.65%) and Vanguard Group Inc. (5.01%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Noubar Afeyan, Roger Pomerantz and Thomas Desrosier. View Institutional Ownership Trends for Seres Therapeutics.

Which institutional investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Jacobs Levy Equity Management Inc., Schroder Investment Management Group, Schroder Investment Management Group, Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp and Lakeview Capital Partners LLC. Company insiders that have sold Seres Therapeutics company stock in the last year include Eric D Shaff, John G Aunins, Roger Pomerantz and Thomas Desrosier. View Insider Buying and Selling for Seres Therapeutics.

Which institutional investors are buying Seres Therapeutics stock?

MCRB stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Perceptive Advisors LLC, ARK Investment Management LLC, Vanguard Group Inc., Marshall Wace North America L.P., Marshall Wace LLP and CVI Holdings LLC. View Insider Buying and Selling for Seres Therapeutics.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $3.65.

How big of a company is Seres Therapeutics?

Seres Therapeutics has a market capitalization of $255.17 million and generates $28.27 million in revenue each year. The biotechnology company earns $-98,940,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe.View Additional Information About Seres Therapeutics.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is http://www.serestherapeutics.com/.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]


MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  651
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel